Shares of Apogee Therapeutics (NASDAQ:APGE) jumped 15% on Monday after the company reported positive 52-week results from ...

As the 2026 American Academy of Dermatology (AAD) annual meeting approaches, MedPage Today is offering a preview of an ...

Apogee Therapeutics shares rally as Phase 2 APEX data show durable atopic dermatitis control with 3- or 6-month dosing.

An experimental treatment for eczema from Apogee Therapeutics induced skin and itch relief comparable to current, widely used ...

For children with atopic dermatitis (AD), dupilumab treatment restores skin barrier function, according to a study published ...

Experts discuss the importance of balancing effective symptom control with quality of life in managing chronic pediatric atopic dermatitis, emphasizing personalized treatment plans that address both ...

Experts discuss the unique challenges of managing atopic dermatitis (AD) in pediatric and adolescent patients, emphasizing the strategic use of topical treatments to improve adherence, reduce ...

A topic dermatitis is a chronic condition that tends to rear its itchy head during certain periods before subsiding — for months, possibly, or even years. It particularly affects the insides of the ...

Shastry is an assistant professor of dermatology at Northwestern Feinberg School of Medicine in Chicago. The information here represents her knowledge and experience as a medical professional. She was ...

If you’re a person of color, finding the right treatment for atopic dermatitis, a common form of eczema, can be challenging. Even though the disease is more prevalent in Black Americans than white ...

If none of your atopic dermatitis treatments have worked, you may be experiencing burnout (or treatment fatigue). Here's what ...

New research links atopic dermatitis to S1P signalling pathways driving inflammation. Learn how this could shape future ...